Publications


Publications, Projects & Awards

Organized by program & group, as selected by each corresponding VHIO Principal Investigator

Please click on the corresponding programs below

Experimental Therapeutics Group

Imagen

Principal Investigator
› Violeta Serra

Medical Oncologists
› Cristina Cruz
› Jordi Rodón

Post-Doctoral Fellows
› Alba Llop-Guevara
› Marta Palafox

Graduate Students
› Marta Castroviejo-Bermejo
› Albert Gris-Oliver
› Mònica Sánchez-Guixé

Technicians
› Judit Grueso
› Marta Guzmán
› Olga Rodríguez

PUBLICATIONS

  • CDK12 inhibition reverses de novo and acquired PARP inhibitor resistance in BRCA wild-type and mutated models of triple-negative breast cancer. Johnson SF, Cruz C, Greifenberg AK, Dust S, Stover DG, Chi D, Primack B, Cao S, Bernhardy AJ, Coulson R, Lazaro JB, Kachupurakkal B, Sun H, Unitt C, Moreau LA, Sarosiek KA, Scaltriti M, Juric D, Baselga J, Richardson AL, Rodig SJ, D’Andrea AD, Balmaña J, Johnson N, Geyer M, Serra V, Lim E*, Shapiro GI*. Cell Reports. Nov 22;17(9):2367-2381. doi: 10.1016/j.celrep.2016.10.077. IF: 7.870
  • PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer. Brasó-Maristany F, Filosto S, Catchpole S, Marlow R, Quist J, Francesch-Domenech E, Plumb DA, Zakka L, Gazinska P, Liccardi G, Meier P, Gris-Oliver A, Cheang MCU, Perdrix-Rosell A, Shafat M, Noël E, Patel N, McEachern K, Scaltriti M, Castel P, Noor F, Buus R, Mathew S, Watkins J, Serra V, Marra P, Grigoriadis A & Tutt AN. Nature Medicine, Nov;22(11):1303-1313. IF: 30.357.
  • A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds. Bruna A, Rueda OM, Greenwood W, Batra AS, Callari M, Batra RN, Pogrebniak K, Sandoval J, Cassidy JW, Tufegdzic-Vidakovic A, Sammut SJ, Jones L, Provenzano E, Baird R, Eirew P, Hadfield J, Eldridge M, McLaren-Douglas A, Barthorpe A, Lightfoot H, O'Connor MJ, Gray J, Cortes J, Baselga J, Marangoni E, Welm AL, Aparicio S, Serra V, Garnett MJ, Caldas C. Cell. 2016 Sep 22;167(1):260-274.e22. IF: 28.710.
  • Gain- and Loss-of-Function Mutations in the Breast Cancer Gene GATA3 Result in Differential Drug Sensitivity. Mair B, Konopka T, Kerzendorfer C, Sleiman K, Salic S, Serra V, Muellner MK, Theodorou V, Nijman SM. PLoS Genet. 2016 Sep 2;12(9):e1006279. IF: 7.528.
  • Stratification and therapeutic potential of PML in metastatic breast cancer. Martín-Martín N, Piva M, Urosevic J, Aldaz P, Sutherland JD, Fernández-Ruiz S, Arreal L, Torrano V, Cortazar AR, Planet E, Guiu M, Radosevic-Robin N, Garcia S, Macías I, Salvador F, Domenici G, Rueda OM, Zabala-Letona A, Arruabarrena-Aristorena A, Zúñiga-García P, Caro-Maldonado A, Valcárcel-Jiménez L, Sánchez-Mosquera P, Varela-Rey M, Martínez-Chantar ML, Anguita J, Ibrahim YH, Scaltriti M, Lawrie CH, Aransay AM, Iovanna JL, Baselga J, Caldas C, Barrio R, Serra V, Vivanco Md, Matheu A, Gomis RR, Carracedo A. Nat Commun. 2016 Aug 24;7:12595. IF: 11.329.
  • Cancer network activity associated with therapeutic response and synergism. Serra-Musach J, Mateo F, Capdevila-Busquets E, de Garibay GR, Zhang X, Guha R, Thomas CJ, Grueso J, Villanueva A, Jaeger S, Heyn H, Vizoso M, Pérez H, Cordero A, Gonzalez-Suarez E, Esteller M, Moreno-Bueno G, Tjärnberg A, Lázaro C, Serra V, Arribas J, Benson M, Gustafsson M, Ferrer M, Aloy P, Pujana MÀ. Genome Med. 2016 Aug 24;8(1):88. IF: 5.850.
  • BRCA1185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1. Drost R, Dhillon KK, van der Gulden H, van der Heijden I, Brandsma I, Cruz C, Chondronasiou D, Castroviejo-Bermejo M, Boon U, Schut E, van der Burg E, Wientjens E, Pieterse M, Klijn C, Klarenbeek S, Loayza-Puch F, Elkon R, van Deemter L, Rottenberg S, van de Ven M, Dekkers DH, Demmers JA, van Gent DC, Agami R, Balmaña J, Serra V, Taniguchi T, Bouwman P, Jonkers J Clin Invest. 2016 Jul 25. pii: 70196. IF: 12.575.
  • Early adaptation and acquired resistance to CDK4/6 inhibition in estrogen receptor positive breast cancer. Herrera-Abreu M*, Palafox M*, Asghar U, Rivas MA, Cutts RJ, Garcia-Murillas I, Pearson A, Guzman M, Rodriguez O, Grueso J, Bellet M, Cortés J, Elliott R, Pancholi S, Baselga J, Dowsett M, Martin LA, Turner NC*, Serra V*. Cancer Research. 2016 Apr 1;76(8):2301-13. IF: 9.329.
  • The BRCA1-Δ11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapy Resistance. Wang Y, Bernhardy AB, Cruz C, Krais JJ, Nacson J, Nicolas E, Peri S, van der Gulden H, van der Heiiden I, O’Brien SW, Zhang Y, Harrell MI, Johnson SF, Candido Dos Reis FJ, Pharoah PDP, Karlan B, Gourley C, Lambrechts D, Chenevix-Trench G, Olsson H, Benitez JJ, Greene MH, Gore M, Nussbaum R, Sadetzki S, Gayther SA, Kjaer SK, kConFab Investigators, D’Andrea AD, Shapiro GI, Wiest DL, Connolly DC, Daly MB, Swisher EM, Bouwman P, Jonkers J, Balmaña J, Serra V and Johnson N. Cancer Research. 2016, May 1;76(9):2778-90. IF: 9.329.

PROJECTS

  • Targeting PI3K and CDK4/6 in breast cancer: Integrative Biomarkers of Response (CCR15330331)
    Principal Investigator: Violeta Serra
    Funding Agency: Susan G Komen Foundation
    Duration: 2015-2018
  • Targeting PI3K and CDK4/6 in breast cancer (CP14/00028)
    Principal Investigator: Violeta Serra
    Funding Agency: ISCIII (Spanish Ministry of Health)
    Duration: 2015-2019
  • Inhibition of PI3K in breast cancer: in-depth analysis of the predictive factors and rational design of therapeutic combinations (PI13/01704)
    Principal Investigator: Violeta Serra
    Funding Agency: ISCIII (Spanish Ministry of Health)
    Duration: 2014-2016
  • Clinical utility of tumor heterogeneity in triple negative breast cancer and high-grade serous ovarian carcinoma for prediction of therapy response (TH4RESPONS)
    Research Partner PI: Violeta Serra. Consortium coordinator: Manfred Dietel
    Funding Agency: ERA-NET
    Duration: 2016-2019
  • Acknowledged Emerging Research Group (SGR): Experimental Therapeutics in Breast Cancer (2014-SGR-1331)
    Group Coordinator: Violeta Serra
    Funding Agency: AGAUR (Catalan Agency for Research)
    Duration: 2014-2016
  • Deciphering PI3K biology in health and disease (PhD)
    Research Partner PI: Violeta Serra and Jordi Rodón. Consortium coordinator: Mariona Graupera
    Funding Agency: European Commission
    Duration: 2016-2019

AWARDS

  • Miguel Servet Mobility Award as a Visiting Scientist at C. Caldas´ Laboratory of Breast Cancer Functional Genomics, Cancer Research UK, Cambridge Cancer Institute (UK).

Growth Factors Group

Imagen

Principal Investigator
› Joaquín Arribas

Scientific Manager
› Cristina Bernadó

Medical Oncologist
› César Serrano

Post-Doctoral Fellows
› Cristina Bernadó
› Beatriz Morancho
› Mercedes Nadal
› Bhavna Rani
› Verónica Rodilla

Masters Student
› Rita Casas

Graduate Students
› Faiz Bilal
› Irene Rius
› Rocio Vicario
› Junjie Zhang

Technicians
› Marta Escorihuela
› Antoni Luque
› David Olivares
› Ismael Varela

PUBLICATIONS

  • Morancho B, Zacarías-Fluck M, Esgueva A, Bernadó-Morales C, Di Cosimo S, Prat A, Cortés J, Arribas J, Rubio IT. Modeling anti-IL-6 therapy using breast cancer patient-derived xenografts. Oncotarget. 2016 Sep 1. Vol. 7, No. 42. doi: 10.18632/oncotarget.11815. *Co-corresponding authors.
  • Hutchinson E, Pujana MA, Arribas J. Cancer therapeutic resistance: progress and perspectives. Drugs Today (Barc). 2016 Jun;52(6):347-54.
  • Serra-Musach J, Mateo F, Capdevila-Busquets E, de Garibay GR, Zhang X, Guha R, Thomas CJ, Grueso J, Villanueva A, Jaeger S, Heyn H, Vizoso M, Pérez H, Cordero A, Gonzalez-Suarez E, Esteller M, Moreno-Bueno G, Tjärnberg A, Lázaro C, Serra V, Arribas J, Benson M, Gustafsson M, Ferrer M, Aloy P, Pujana MA. Cancer network activity associated with therapeutic response and synergism. Genome Med. 2016 Aug 24;8(1):88. doi: 10.1186/s13073-016-0340-x.
  • Hergueta-Redondo M, Sarrio D, Molina-Crespo Á, Vicario R, Bernadó-Morales C, Martínez L, Rojo-Sebastián A, Serra-Musach J, Mota A, Martínez-Ramírez Á, Castilla MÁ, González-Martin A, Pernas S, Cano A, Cortes J, Nuciforo PG, Peg V, Palacios J, Pujana MÁ, Arribas J, Moreno-Bueno G. Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cáncer. Oncotarget. 2016 Jul 22. Vol. 7, No. 35. doi: 10.18632/oncotarget.10787.
  • Esparís-Ogando A, Montero JC, Arribas J, Ocaña A, Pandiella A. Targeting the EGF/HER Ligand-Receptor System in Cancer. Curr. Pharm. Des. 2016 22(39):5887-5898
  • Nuciforo P, Thyparambil S, Aura C, Garrido-Castro A, Marta Vilaro M, Peg V, Jimenez J, Hoos W, Burrows J, Todd Hembrough T, Ferreres JC, Perez-Garcia J, Arribas J, Cortes J, Scaltriti M. High HER2 protein levels measured by multiplex mass spectrometry correlate with increased overall survival in patients treated with anti-HER2 therapy. Mol. Oncol. 2016 Jan;10(1):138-47. doi: 10.1016/j.molonc.2015.09.002.

PROJECTS

  • CIBER-ONC Breast Cancer Program.
  • Immunotherapy Against HER2-positive Breast and Gastric Cancers.
  • Novel therapies against HER2-positive breast tumors: targeting oncogene-induced senescence and the immune system.
  • Immunoterapia contra tumores de mama apositivos para p95HER2.
  • Novel immunotherapies to treat colorectal and breast cancer.
  • Clinical Impact of Intratumor heterogeneity in metastatic breast cancer – CCE.
  • Nuevas Estrategias para Tratar el Cáncer de Mama Positivo para HER2.
  • PI3K/AKT/Mtor and RAS/MEK/ERK pathway inhibition in gastrointestinal stromal tumors (GISTs): Identifiying novel treatment strategies to overcome resistance to KIT/PDGFRA inhibition in GIST.
  • Immune profiles during breast cancer treatment. Indication of biomarkers of sensitivity/resistance.
  • Overcoming heterogeneity in gastrointestinal stromal tumors: early detection of resistant subpopulations for tyrosin kinase inhibitor rotation.
  • Characterizarion of resistances to ADCs targeting HER2.

Mouse Models of Cancer Therapies Group

Imagen

Principal Investigator
› Laura Soucek

Staff Scientist
› Jonathan Whitfield

Post-Doctoral Fellow
› Marie-Eve Beaulieu
› Silvia Casacuberta
› Mariano F. Zacarias

Graduate Students
› Toni Jauset González
› Sandra Martínez
› Daniel Massó Vallés

Technicians
› Virginia Castillo
› Laia Foradada
› Érika Serrano del Pozo

Visiting Postdoctoral Scholar
› Roberta Laranga

PUBLICATIONS

  • Massó-Vallés D, Jauset T, Soucek L. Ibrutinib repurposing: from B cell malignancies to solid tumors. Oncoscience. 2016 Jun 10;3(5-6):147-8.
  • Fiorentino FP, Tokgün E, Solé-Sánchez S, Giampaolo S, Tokgün O, Jauset T, Kohno T, Perucho M, Soucek L, Yokota J. Growth Suppression by MYC Inhibition in Small Cell Lung Cancer Cells with TP53 and RB1 Inactivation. Oncotarget. 2016 May 24;7(21):31014-28.

PROJECTS

New Projects:

  • Retos de Colaboración grant from the Spanish Ministry of Economy, Industry and Competitiveness. Title: Preclinical development of Omomyc-CPP as a therapy for cancer treatment. 2016-2019.
  • Instituto de Salud Carlos III (Institute of Health Carlos III, ISCIII) FIS grant - Fondo de Investigación en Salud (Health Research Fund). Title: In vivo validation of innovative anti-Myc therapies in glioblastoma. 2016-2019.
  • European Research Council – ERC (European Commission) Proof-of-Concept Grant. Title: Developing an anti-Myc cell-penetrating peptide for cancer treatment. 2016-2017.
  • Grant from Catalonia Trade & Investment (a unit of ACCIÓ, the Agency for Business Competitiveness). Title: Pre-clinical development of OmomycCPP: characterization of the immune response. 2016.
  • SME Instrument Phase I grant by the European Commission within the Horizon 2020 Program to Peptomyc S.L. Title: Feasibility study of a novel treatment for cancer based on a recombinant peptide Therapy. 2016.
  • FERO Foundation grant. Title: Use of liposomal nanotechnology to optimize systemic administration of Omomyc in metastatic breast cancer. 2016.

Ongoing:

  • BBVA Foundation Grant in Biomedicine. Title: Validation of an innovative anti-Myc therapy in glioblastoma. 2015-2017.
  • Grant for Emerging Research Group of Catalunya from the Agency for Management of University and Research Grants (AGAUR). 2014-2016.
  • European Research Council - ERC Consolidator Grant. Title: Pushing Myc inhibition towards the clinic. 2014-2019.
  • Instituto de Salud Carlos III (Institute of Health Carlos III, ISCIII) FIS grant - Fondo de Investigación en Salud (Health Research Fund). Title: Advancing Myc inhibition towards the clinic for the treatment of lung cancer. 2014-2017.
  • Worldwide Cancer Research Grant. Title: Advancing Myc inhibition towards the clinic: characterization of an Omomyc cell-penetrating peptide. 2013-2016.

AWARDS

  • European Research Council ERC Proof-of-Concept grant within the framework of the EU Horizon 2020 Program. Title: Developing an anti-Myc cell-penetrating peptide for cancer treatment.
  • Laura´s group also received a grant from the Instituto de Salud Carlos III (Institute of Health Carlos III, ISCIII) for a FIS - Fondo de Investigación en Salud (Health Research Fund) to support the project entitled In vivo validation of innovative anti-Myc therapies in glioblastoma.
  • She also received a Retos de Colaboración grant from the Spanish Ministry of Economy, Industry and Competitiveness for the Preclinical development of Omomyc-CPP as a therapy for cancer treatment, as well as funding from the FERO Foundation for the project: Use of liposomal nanotechnology to optimize systemic administration of Omomyc in metastatic breast cancer.
  • Peptomyc S.L. was awarded an SME Instrument Phase I by the European Commission within the Horizon 2020 Program. Title: Feasibility study of a novel treatment for cancer based on a recombinant peptide therapy — PEPTO1. Of note, this grant was the only one awarded in biotechnology for this specific call.
  • Peptomyc S.L. also received a Business Plan Aggregator Prize at the EIT Health Summit, as well as a grant from Catalonia Trade & Investment (a unit of ACCIÓ, the Agency for Business Competitiveness), for the Pre-clinical development of Omomyc-CPP: characterization of the immune response.
  • Daniel Massó-Valles, PhD student in the lab, was awarded a Nature Reviews Cancer poster prize at the VHIO -“la Caixa” Banking Foundation´s International Symposium: Towards Predictive Cancer Models, 26 – 27 May 2016. Title of poster: Targeting Myc in Breast Cancer Metastasis.

Tumor Biomarkers Group

Imagen

Principal Investigator
› Josep Villanueva

Post-Doctoral Fellows
› Mercè Juliachs
› Juan Manuel Duran
› Olga Méndez
› Nathalie Meo-Evoli

Graduate Student
› Mireia Pujals

Technicians
› Ana Matres
› Candida Salvans

PROJECTS

  • Diagnostic and Therapeutic implications of extracellular HMGA1 in Breast Cancer
    Agency : Susan G Komen
    Duration: 15/09/2015 - 15/09/2017
    Principal Investigator: Josep Villanueva
  • Characterization of the role of HMGA1 as a mediator of tumor progression in breast cancer
    Agency: Instituto Salud Carlos III
    Duration: 1/01/2016 - 31/12/2018
    Principal Investigator: Josep Villanueva